2025 · The International journal on drug policy · paywalled
Patient preferences for simplified hepatitis C testing modalities among people at risk of hepatitis C infection in Australia: the SELECT study
Stevens et al.
The finding, in our words
Among 404 Australians at risk of hepatitis C, 91% of those with prior infection selected point-of-care RNA testing, citing rapid results, while 72% of those without prior infection preferred staff-assisted antibody testing. Offering rapid, staff-assisted testing improves uptake among people who inject drugs, those experiencing homelessness and those receiving opioid agonist therapy.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.
The study validated a semi-quantitative protocol for Epstein-Barr virus serology using dried blood spots, demonstrating 98.8% sensitivity and 96.5% specificity compared to paired venous serum samples. The successful validation in a self-sampling cohort confirms the suitability of this patient-centric microsampling approach for large-scale seroprevalence studies and decentralised trials.
In a pilot mixed-methods study of youth with HIV, mailed HemaSpot-HF kits enabled home-based dried blood spot collection that participants found feasible and acceptable, supporting remote viral load monitoring and a self-management model for decentralised care.
The study found that quantitative dried blood spot sampling provided high clinical agreement for tacrolimus and creatinine monitoring, with patients rating the self-collection devices as user-friendly. These results support the feasibility of decentralised therapeutic drug monitoring for immunosuppressants.
In a cohort of 62 participants evaluating home self-collection with the TassoPlus device, 38 returned samples, with 29% excluded due to insufficient plasma volume below 200 ΔL. Although viral load measurements in adequate samples correlated well with conventional testing (r = 0.800), the high failure rate and missed detection in low-volume viremic samples indicate that further technical refinements are necessary before clinical adoption.